Impact of vedolizumab therapy on extra-intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV-IBD cohort - Archive ouverte HAL
Article Dans Une Revue Alimentary Pharmacology and Therapeutics Année : 2018

Impact of vedolizumab therapy on extra-intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV-IBD cohort

1 Service de gastro-entérologie [Henri Mondor AP-HP, Créteil]
2 EC2M3 - Early detection of Colon Cancer using Molecular Markers and Microbiota (EA 7375)
3 Service d'Hépato-gastro-entérologie [CHRU Nancy]
4 NGERE - Nutrition-Génétique et Exposition aux Risques Environnementaux
5 Hôpital Nord [CHU - APHM]
6 CIC - Centre d’Investigation Clinique Marseille Nord
7 Servcie Hépato-gastroentérolgie et Nutrition clinique [CHU Nice]
8 Service Hépato-gastroentérologie [Hôpital Claude Huriez, Lille]
9 LIRIC - Lille Inflammation Research International Center - U 995
10 Service de Gastro-entérologie et Hépatologie [CHU Saint-Etienne]
11 M2iSH - Microbes, Intestin, Inflammation et Susceptibilité de l'Hôte
12 Service Hépato-Gastro-Entérologie [CHU Clermont-Ferrand]
13 Service de Gastro-entérologie et assistance nutritive [Hôpital Beaujon, AP-HP]
14 IMAD - Institut des maladies de l'appareil digestif [Nantes]
15 Service d'Hépato-Gastroentérologie [CHU Nantes]
16 Département d'Hépato-Gastroentérologie et de Transplantation Hépatique [CHU Saint-Eloi]
17 CHU Saint-Antoine [AP-HP]
18 Service d'Hépato-gastro-entérologie [Hôpital Bicêtre, AP-HP]
19 Service d'Hépatogastroentérologie [Hôpital Lyon-Sud, HCL]
20 CHU Bordeaux - Centre Hospitalier Universitaire de Bordeaux
21 Service d'Hépato-Gastro-Entérologie [Hôpital Saint-Louis, AP-HP]
22 Service d'Hépato-Gastroentérologie [CHU Rouen]
23 ADEN - Nutrition, inflammation et dysfonctionnement de l'axe intestin-cerveau
24 Service de Gastroentérologie et pancréatologie [CHU Toulouse]
25 Service de Gastro-Entérologie [CHRU Besançon]
26 Service d'Hépato-Gastro-Enterologie et Nutrition [CHU Caen]
27 Département d'Hépato-Gastroentérologie [Hôpital Trousseau, Tours]
28 Service de Hépato-gastro-entérologie et cancérologie digestive [Hôpital Bichat - Claude Bernard]
29 Service des Maladies de l'Appareil Digestif [CHU Rennes]
30 Service de Gastro-entérologie et hépatologie [Hôpital Cochin], [AP-HP]
31 Service d'Hépato-gastroentérologie [CHU Amiens-Picardie]
32 Service de rhumatologie [CHU Henri Mondor]
33 Service de Gastroentérologie [Hôpital Beaujon]
* Getaid Observ-Ibd
  • Fonction : Auteur

Résumé

Background: The effectiveness of vedolizumab as a treatment for extraintestinal manifestations (EIM) is questionable due to its gut-specificity. Aim: To assess effectiveness of vedolizumab for EIM in patients with inflammatory bowel disease (IBD) in a large real-life experience cohort. Methods: Between June and December 2014, 173 patients with Crohn's disease and 121 with ulcerative colitis were treated with vedolizumab. Patients were followed until week 54. EIM activity was assessed at weeks 0, 6, 14, 22, 30 and 54 by using a 3-step scale: complete remission, partial response and no response. Results: At baseline, 49 (16.7%) patients had EIMs of which 47 had inflammatory arthralgia/arthritis, four had cutaneous lesions and two had both rheumatologic and skin EIM. At week 54, 21 (44.7%) patients had complete remission for inflammatory arthralgia/arthritis and three (75%) for cutaneous EIM. In multivariate analysis, complete remission of inflammatory arthralgia/arthritis was associated with clinical remission of IBD (OR = 1.89, IC95% [1.05-3.41], P = .03) and recent onset of inflammatory arthralgia/arthritis (OR = 1.99, IC95% [1.12-3.52], P = .02). During the follow-up period, 34 (13.8%) patients without any EIM at baseline, developed incident cases of inflammatory arthralgia/arthritis consisting mostly of peripheral arthralgia without evidence of arthritis and 14 (4.8%) incident cases of paradoxical skin manifestation. Conclusion: Vedolizumab therapy is commonly associated with improvement in EIM. This was associated with quiescent IBD and recent EIM. However, paradoxical skin manifestation and inflammatory arthralgia/arthritis may occur upon vedolizumab therapy.

Dates et versions

hal-02013755 , version 1 (11-02-2019)

Identifiants

Citer

Sara Tadbiri, Laurent Peyrin-Biroulet, Mélanie Serrero, Jérôme Filippi, Benjamin Pariente, et al.. Impact of vedolizumab therapy on extra-intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV-IBD cohort. Alimentary Pharmacology and Therapeutics, 2018, 47 (4), pp.485-493. ⟨10.1111/apt.14419⟩. ⟨hal-02013755⟩
255 Consultations
0 Téléchargements

Altmetric

Partager

More